Dolutegravir Resistance and Failure in a Kenyan Patient

Affiliations

¹ Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya.
² Institute of Human Virology and Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore.

Comment

Loice Achieng et al. J Infect Dis. 2019.

. 2019 Jan 1;219(1):165-167.

doi: 10.1093/infdis/jiy436.

¹ Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya.
² Institute of Human Virology and Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore.

No abstract available

Comment in

Reply to Achieng and Riedel.
Pham HT, Goring ME, Mesplède T. Pham HT, et al. J Infect Dis. 2019 Jan 1;219(1):167-169. doi: 10.1093/infdis/jiy437. J Infect Dis. 2019. PMID: 30165488 No abstract available.

Resistance to Dolutegravir-A Chink in the Armor?
Kuritzkes DR. Kuritzkes DR. J Infect Dis. 2018 Jul 24;218(5):673-675. doi: 10.1093/infdis/jiy186. J Infect Dis. 2018. PMID: 29617815 Free PMC article. No abstract available.
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.
Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans JJC, Schuurman R, van de Vijver DAMC, Boers PHM, Gruters RA, Boucher CAB, van Kampen JJA. Wijting IEA, et al. J Infect Dis. 2018 Jul 24;218(5):688-697. doi: 10.1093/infdis/jiy176. J Infect Dis. 2018. PMID: 29617822
The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.
Pham HT, Labrie L, Wijting IEA, Hassounah S, Lok KY, Portna I, Goring ME, Han Y, Lungu C, van der Ende ME, Brenner BG, Boucher CA, Rijnders BJA, van Kampen JJA, Mesplède T, Wainberg MA. Pham HT, et al. J Infect Dis. 2018 Jul 24;218(5):698-706. doi: 10.1093/infdis/jiy175. J Infect Dis. 2018. PMID: 29617824 Free PMC article.